US5679399A
(en)
|
1987-07-17 |
1997-10-21 |
Bio Barrier, Inc. |
Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
|
US5549924A
(en)
*
|
1987-07-17 |
1996-08-27 |
Robin Renee Thill Shlenker |
Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
|
JPH01153633A
(ja)
*
|
1987-12-10 |
1989-06-15 |
Kyorin Pharmaceut Co Ltd |
経皮吸収製剤
|
US5633009A
(en)
*
|
1990-11-28 |
1997-05-27 |
Sano Corporation |
Transdermal administration of azapirones
|
US5613958A
(en)
*
|
1993-05-12 |
1997-03-25 |
Pp Holdings Inc. |
Transdermal delivery systems for the modulated administration of drugs
|
US20050152950A1
(en)
*
|
1995-11-13 |
2005-07-14 |
Saffran Bruce N. |
Method and apparatus for macromolecular delivery using a coated membrane
|
AU2247997A
(en)
*
|
1996-01-29 |
1997-08-20 |
Savor, Evelyn P. |
Method of treating undesired uterine contractions using optically pure R-or RR-isomers of adrenergic beta-2 agonists
|
US5708036A
(en)
*
|
1996-01-29 |
1998-01-13 |
Pesterfield, Jr.; E. Charles |
Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
|
US5837289A
(en)
*
|
1996-07-23 |
1998-11-17 |
Grasela; John C. |
Transdermal delivery of medications using a combination of penetration enhancers
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
GB9719076D0
(en)
*
|
1997-09-09 |
1997-11-12 |
Movevirgo Limited |
A material for producing a medical dressing and a medical dressing produced using the material
|
CN100357143C
(zh)
*
|
1998-01-20 |
2007-12-26 |
易通公司 |
起步发动机扭矩限制
|
US5900249A
(en)
*
|
1998-02-09 |
1999-05-04 |
Smith; David J. |
Multicomponent pain relief topical medication
|
SE9803240D0
(sv)
*
|
1998-09-24 |
1998-09-24 |
Diabact Ab |
A pharmaceutical composition having a rapid action
|
KR100369779B1
(ko)
*
|
1999-07-12 |
2003-01-29 |
주식회사 엘지생명과학 |
교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
|
US7713546B1
(en)
*
|
2001-04-03 |
2010-05-11 |
Soft Gel Technologies, Inc. |
Corosolic acid formulation and its application for weight-loss management and blood sugar balance
|
US20070218087A1
(en)
*
|
2001-12-07 |
2007-09-20 |
Norbert Hoenzelaer |
Method of controlled release of vanillin for nasal and/or pulmonary uptake
|
DE10200578A1
(de)
*
|
2002-01-09 |
2003-07-10 |
Roehm Gmbh |
Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
CA2492654A1
(fr)
*
|
2002-07-16 |
2004-01-22 |
University Of South Florida |
Proteine immunosuppressive humaine
|
EP2316459B1
(fr)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
Composants de 2,4-pyrimidinediamine pour être utilisés dans des procédés de traitement ou de prévention des maladies auto-immunes
|
US7241456B2
(en)
*
|
2002-10-25 |
2007-07-10 |
Australian Importers Ltd. |
Formulations for topical delivery of bioactive substances and methods for their use
|
EP2027854A1
(fr)
|
2002-11-18 |
2009-02-25 |
Yaupon Therapeutics, Inc. |
Utilisations analgésiques pour les promédicaments à base de norkétamine et kétamine/norkétamine
|
WO2004075075A1
(fr)
*
|
2003-01-21 |
2004-09-02 |
Alza Corporation |
Modele informatique de liberation transdermique de medicament
|
WO2004094457A2
(fr)
*
|
2003-04-16 |
2004-11-04 |
Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University |
Composition peptidomimetique rgd stable
|
JP4741491B2
(ja)
|
2003-08-07 |
2011-08-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
|
US20050186269A1
(en)
*
|
2004-02-25 |
2005-08-25 |
Udell Ronald G. |
Stabilized feverfew formulations
|
US8168600B2
(en)
*
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
US20060051435A1
(en)
*
|
2004-08-19 |
2006-03-09 |
Udell Ronald G |
Nutritional supplement for body fat reduction
|
US9050393B2
(en)
|
2005-02-08 |
2015-06-09 |
Bruce N. Saffran |
Medical devices and methods for modulation of physiology using device-based surface chemistry
|
US20070104805A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Udell Ronald G |
Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
|
AT502717A1
(de)
*
|
2005-11-09 |
2007-05-15 |
Omnica Gmbh |
Pharmazeutische verwendung einer verbindung
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
EP2007877B1
(fr)
*
|
2006-02-28 |
2013-04-17 |
The Trustees of Columbia University in the City of New York |
Procedes d'agregation compacte de cellules dermiques
|
AT503329A1
(de)
*
|
2006-03-02 |
2007-09-15 |
Omnica Gmbh |
Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
|
AT503521A1
(de)
*
|
2006-05-05 |
2007-11-15 |
Omnica Gmbh |
Verwendung eines extraktes von kiwi-frucht
|
US8278358B2
(en)
*
|
2006-07-06 |
2012-10-02 |
Omnica Gmbh |
Lipoic acid derivatives
|
JP2008044926A
(ja)
*
|
2006-08-14 |
2008-02-28 |
Trustees Of Columbia Univ In The City Of New York |
Wnt信号伝達に関係した分泌タンパク質
|
EP2089369B1
(fr)
|
2006-10-19 |
2011-02-02 |
Rigel Pharmaceuticals, Inc. |
Derives 2,4 -pyrimidinediamine en tant qu'inhibiteurs de kinases jak pour le traitement de maladies autoimmunes
|
EP2420505A1
(fr)
|
2006-11-21 |
2012-02-22 |
Rigel Pharmaceuticals, Inc. |
Promédicaments de composés de 2,4-pyrimidinediamine et leurs utilisations
|
US8623429B2
(en)
|
2007-03-15 |
2014-01-07 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
US7820207B2
(en)
*
|
2007-03-15 |
2010-10-26 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
CA2835910C
(fr)
*
|
2007-04-25 |
2016-06-28 |
Warner Chilcott Company, Llc |
Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques
|
US20080293644A1
(en)
*
|
2007-04-27 |
2008-11-27 |
Thomas Eidenberger |
Guava extract
|
US8034983B2
(en)
*
|
2007-06-06 |
2011-10-11 |
Multi-Tech Specialty Chemicals, Co., Ltd. |
Process for the preparation of xanthophyll crystals
|
EP2234608A2
(fr)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
|
WO2009089380A2
(fr)
*
|
2008-01-08 |
2009-07-16 |
The Trustees Of Columbia University In The City Of New York |
Procédés pour la régulation médiée par p2ry5 de la pousse de cheveux et des mutants de ceux-ci
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
US20090270398A1
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Pyridazine Derivatives
|
US8207205B2
(en)
|
2008-04-21 |
2012-06-26 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising oxadiazole derivatives
|
US8236838B2
(en)
*
|
2008-04-21 |
2012-08-07 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
NZ591234A
(en)
*
|
2008-08-22 |
2012-03-30 |
Sanofi Aventis |
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
|
US20110237528A1
(en)
*
|
2008-09-19 |
2011-09-29 |
Institute For Oneworld Health |
Compositions and methods comprising imidazole and triazole derivatives
|
AR074776A1
(es)
|
2008-12-18 |
2011-02-09 |
Sanofi Aventis |
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
|
EP2382210B1
(fr)
|
2008-12-30 |
2017-03-01 |
Rigel Pharmaceuticals, Inc. |
Inhibiteurs de pyrimidinediamine kinase
|
PE20150621A1
(es)
|
2009-01-23 |
2015-05-07 |
Rigel Pharmaceuticals Inc |
Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
|
US8236862B2
(en)
*
|
2009-02-06 |
2012-08-07 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
CN102482249B
(zh)
|
2009-07-08 |
2016-06-08 |
德米拉(加拿大)公司 |
用于治疗皮肤病症或疾病状态的tofa类似物
|
US20110034415A1
(en)
|
2009-07-20 |
2011-02-10 |
Thomas Eidenberger |
Walnut extracts for nutraceutical applications
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
EP2493468A1
(fr)
|
2009-10-30 |
2012-09-05 |
Sanofi |
Dérivés de l'acide aminobenzoïque destinés à être utilisés dans le traitement de troubles associés à la déshydrogénase
|
US20110144200A1
(en)
|
2009-12-14 |
2011-06-16 |
Thomas Eidenberger |
Combination of carotenoids and epi-lutein
|
CA2785439A1
(fr)
|
2009-12-23 |
2011-06-30 |
Sanofi |
[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones et leur synthese
|
RS53456B
(en)
|
2009-12-23 |
2014-12-31 |
Sanofi |
[4 [4- (5-AMINOMETHYL-2-FLUOR-PHENYL) -PIPERIDIN-1-IL] - (1H-Pyrrolo-pyridin-IL) -METHANONE AND THEIR SYNTHESIS
|
WO2011130716A2
(fr)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
Nanostructures contenant de la vitamine b12 pour l'administration facilitée de médicaments à travers des barrières biologiques
|
WO2011133596A1
(fr)
|
2010-04-20 |
2011-10-27 |
Institute For Oneworld Health |
Composés, compositions et méthodes impliquant des dérivés de 1,3,4-oxadiazole
|
WO2011133600A1
(fr)
|
2010-04-20 |
2011-10-27 |
Institute For Oneworld Health |
Composés, compositions et méthodes impliquant des dérivés sulfamidés de pyridazine
|
EP2563771B1
(fr)
|
2010-04-24 |
2015-11-25 |
Viamet Pharmaceuticals, Inc. |
Composés inhibiteurs de métalloenzyme
|
ES2880622T3
(es)
|
2010-07-28 |
2021-11-25 |
Rigel Pharmaceuticals Inc |
Composiciones y procedimientos para la inhibición de la ruta de JAK
|
US8968755B2
(en)
|
2010-10-23 |
2015-03-03 |
Joel Schlessinger |
Topical base and active agent-containing compositions, and methods for improving and treating skin
|
US8685381B2
(en)
|
2010-10-23 |
2014-04-01 |
Joel Schlessinger |
Topical base and active agent-containing compositions, and methods for improving and treating skin
|
US9056855B2
(en)
|
2010-10-28 |
2015-06-16 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
JP5948337B2
(ja)
|
2010-11-02 |
2016-07-06 |
ザ トラスティース オブ コロンビア ユニバーシティ インザ シティ オブ ニューヨーク |
脱毛症の治療方法
|
BR112013011830B1
(pt)
|
2010-11-13 |
2022-03-15 |
Innocrin Pharmaceuticals, Inc |
Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
|
BR112013014484A2
(pt)
|
2010-12-13 |
2016-07-19 |
Viamet Pharmaceuticals Inc |
compostos inibidores de metaloenzimas
|
US9169182B2
(en)
|
2011-02-25 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chrysophaentin analogs that inhibit FtsZ protein
|
EP2683410A2
(fr)
|
2011-03-08 |
2014-01-15 |
Access Pharmaceuticals, Inc. |
Systèmes de nanovecteurs ciblés pour l'administration de matières actives à travers des membranes biologiques
|
CN105884743B
(zh)
|
2011-06-19 |
2019-08-06 |
威尔金制药(Nc)有限公司 |
金属酶抑制剂化合物
|
KR20140040235A
(ko)
|
2011-06-19 |
2014-04-02 |
비아멧 파마슈티컬즈, 인코포레이티드 |
금속효소 억제제 화합물
|
AU2012273004B2
(en)
|
2011-06-23 |
2017-04-13 |
Mycovia Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
WO2013019169A1
(fr)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Promédicaments du phosphate
|
AU2012301617A1
(en)
|
2011-09-02 |
2014-04-17 |
Salk Institute For Biological Studies |
CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity
|
SI2788343T1
(sl)
|
2011-12-11 |
2019-09-30 |
Viamet Pharmaceuticals (NC), Inc. |
Spojine inhibitorja metaloencimov
|
KR102061137B1
(ko)
|
2012-01-20 |
2019-12-31 |
마이코비아 파마슈티컬즈, 인코포레이티드 |
금속효소 억제제 화합물
|
WO2013142038A2
(fr)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions et procédés destinés à l'inhibition de cathepsines
|
JP6212107B2
(ja)
|
2012-03-29 |
2017-10-11 |
ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
脱毛障害を処置するための方法
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
WO2014012653A1
(fr)
*
|
2012-07-16 |
2014-01-23 |
Grünenthal GmbH |
Patch pharmaceutique pour l'administration transdermique de tapentadol
|
WO2014013014A1
(fr)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Inhibiteurs de jak pour l'activation de populations de cellules souches épidermiques
|
JP2016506930A
(ja)
|
2013-01-25 |
2016-03-07 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
炎症性腸疾患を処置するための化合物および方法
|
CA2907152A1
(fr)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Proteines de fusion et procedes correspondants
|
EP3119415A4
(fr)
|
2014-03-07 |
2017-11-29 |
The Arizona Board of Regents on behalf of the University of Arizona |
Peptides crmp2 non narcotiques ciblant des canaux sodiques pour la douleur chronique
|
WO2015143184A1
(fr)
|
2014-03-19 |
2015-09-24 |
Viamet Pharmaceuticals, Inc. |
Procédé de préparation d'un composé antifongique
|
EP3925979A3
(fr)
|
2014-12-23 |
2022-03-23 |
The Trustees of Columbia University in the City of New York |
Protéines de fusion fgfr-tacc et utilisations associées
|
CN107428724B
(zh)
|
2015-03-19 |
2021-07-02 |
迈科维亚医药公司 |
抗真菌化合物及制备方法
|
WO2017023941A1
(fr)
|
2015-08-04 |
2017-02-09 |
Rigel Pharmaceuticals, Inc. |
Composés benzazole et procédés pour préparer et utiliser les composés
|
ES2858314T3
(es)
|
2015-09-18 |
2021-09-30 |
Mycovia Pharmaceuticals Inc |
Procedimiento para compuesto antifúngico
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
EA038421B1
(ru)
|
2015-12-30 |
2021-08-26 |
ВиПиЭс-3, ИНК. |
Соединения, ингибирующие металлоферменты
|
EP3475263B1
(fr)
|
2016-06-27 |
2022-12-28 |
Rigel Pharmaceuticals, Inc. |
Composés de 2,4-diaminopyrimidine et leur utilisation comme inhibiteurs de irak4
|
US10981928B2
(en)
|
2016-06-29 |
2021-04-20 |
Halo Life Science, Llc |
Methods of making low odor choline salts of an organic compound
|
EP4212523A1
(fr)
|
2016-10-26 |
2023-07-19 |
Rigel Pharmaceuticals, Inc. |
Composés pyrazole amide utilisés en tant qu'inhibiteurs d'irak
|
ES2939232T3
(es)
|
2016-10-26 |
2023-04-20 |
Rigel Pharmaceuticals Inc |
Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
|
RU2764666C2
(ru)
|
2016-12-29 |
2022-01-19 |
Селенити Терапьютикс (Бермуда), Лтд. |
Соединения, ингибирующие металлоферменты
|
WO2018125799A2
(fr)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Composés inhibiteurs des métalloenzymes
|
WO2019006126A1
(fr)
|
2017-06-29 |
2019-01-03 |
Rigel Pharmaceuticals, Inc. |
Inhibiteurs de kinases et leurs procédés de fabrication et d'utilisation
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
PL3788045T3
(pl)
|
2018-05-03 |
2023-10-09 |
Rigel Pharmaceuticals, Inc. |
Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
|
MD3788044T2
(ro)
|
2018-05-03 |
2023-12-31 |
Rigel Pharmaceuticals Inc |
Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
|
WO2020092845A1
(fr)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Modes de réalisation d'un procédé et d'une composition permettant de traiter la leucémie myéloïde aiguë
|
WO2020243612A1
(fr)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Méthode de prévention et de traitement de la thrombose
|
JP2022543843A
(ja)
|
2019-08-08 |
2022-10-14 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
サイトカイン放出症候群を治療するための化合物及び方法
|
EP4013420B1
(fr)
|
2019-08-14 |
2023-11-01 |
Rigel Pharmaceuticals, Inc. |
Procédé de blocage ou d'amélioration du syndrome de libération des cytokines
|
MX2022002292A
(es)
|
2019-08-30 |
2022-06-02 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
|
EP4025568A1
(fr)
|
2019-09-06 |
2022-07-13 |
Rigel Pharmaceuticals, Inc. |
Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
|
US11564930B2
(en)
|
2019-09-06 |
2023-01-31 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
CA3156594A1
(fr)
|
2019-11-07 |
2021-05-14 |
Yan Chen |
Composes heterocycliques inhibiteurs de rip1
|
US20220288047A1
(en)
|
2021-03-03 |
2022-09-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
TW202346291A
(zh)
|
2022-03-23 |
2023-12-01 |
美商雷傑製藥公司 |
作為irak抑制劑的嘧啶—2—基—吡唑化合物
|
WO2023192479A1
(fr)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Inhibiteurs d'irak tricycliques
|